Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R H Begent

Showing results (101-110 of 166) with videos related to

Pageof 17
Sort By:
Journal of the Royal Society of Medicine|September 1, 1980
Radioimmunolocalization of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communicationR H Begent, F Searle, G Stanway, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 1, 1991
Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinomaP A Philip, G J Rustin, J A Ledermann, et al.
The International Journal of Biological Markers|January 1, 1989
Carcinoembryonic antigen levels in germ cell tumoursR N Hitchins, G J Rustin, H D Mitchell, et al.
Oncodevelopmental Biology and Medicine : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1983
Clearance of injected radioactively labelled antibodies to tumour products by liposome-bound second antibodiesP A Keep, F Searle, R H Begent, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibodyA Mayer, K A Chester, J Bhatia, et al.
British Journal of Cancer|December 1, 1994
The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibodyR B Pedley, J A Boden, R Boden, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trialJ Martin, S M Stribbling, G K Poon, et al.
British Journal of Urology|August 1, 1994
The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumoursJ A Ledermann, L Holden, E S Newlands, et al.
International Journal of Cancer|April 15, 1984
Preparation and properties of mouse monoclonal antibody (W14A) to human chorionic gonadotropinF Searle, C S Partridge, A Kardana, et al.
Lancet (London, England)|August 24, 1991
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapyD B Smith, E S Newlands, G J Rustin, et al.
Pageof 17

Showing results (101-110 of 166) with videos related to

Sort By:
Pageof 17
Journal of the Royal Society of Medicine|September 1, 1980
Radioimmunolocalization of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communicationR H Begent, F Searle, G Stanway, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 1, 1991
Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinomaP A Philip, G J Rustin, J A Ledermann, et al.
The International Journal of Biological Markers|January 1, 1989
Carcinoembryonic antigen levels in germ cell tumoursR N Hitchins, G J Rustin, H D Mitchell, et al.
Oncodevelopmental Biology and Medicine : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1983
Clearance of injected radioactively labelled antibodies to tumour products by liposome-bound second antibodiesP A Keep, F Searle, R H Begent, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibodyA Mayer, K A Chester, J Bhatia, et al.
British Journal of Cancer|December 1, 1994
The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibodyR B Pedley, J A Boden, R Boden, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trialJ Martin, S M Stribbling, G K Poon, et al.
British Journal of Urology|August 1, 1994
The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumoursJ A Ledermann, L Holden, E S Newlands, et al.
International Journal of Cancer|April 15, 1984
Preparation and properties of mouse monoclonal antibody (W14A) to human chorionic gonadotropinF Searle, C S Partridge, A Kardana, et al.
Lancet (London, England)|August 24, 1991
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapyD B Smith, E S Newlands, G J Rustin, et al.
Pageof 17